Coagulopathy and hemodialysis significantly increase odds of post-ERCP bleeding in patients with cirrhosisRisk factors for bleeding during and after ERCP procedures identified

This meta-analysis synthesized data from a large population of 149,870 patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) to identify risk factors associated with post-ERCP bleeding. The study specifically examined the impact of clinical conditions, procedural techniques, and patient demographics on bleeding outcomes. The analysis included several key variables, including male gender, anticoagulation therapy, cirrhosis, hemodialysis, coagulopathy, endoscopic sphincterotomy, precut sphincterotomy, and intraoperative bleeding.

The primary outcome of the analysis was the occurrence of post-ERCP bleeding. The meta-analysis reported several significant associations. Patients with coagulopathy showed the highest increase in risk, with an OR of 11.01 (95% CI, 2.50-48.40). Patients undergoing hemodialysis also showed a substantial increase in risk with an OR of 5.82 (95% CI, 3.32-10.18). Other significant findings included an OR of 3.19 (95% CI, 1.69-6.01) for endoscopic sphincterotomy (EST), an OR of 2.75 (95% CI, 1.66-4.56) for anticoagulation therapy, and an OR of 2.57 (95% CI, 1.80-3.66) for intraoperative bleeding. Patients with cirrhosis showed an OR of 2.54 (95% CI, 1.76-3.65), while those undergoing precut sphincterotomy showed an OR of 2.24 (95% CI, 1.52-3.30). Male gender was also associated with increased risk, though the effect size was smaller at OR 1.24 (95% CI, 1.05-1.46).

Secondary outcomes included postsphincterotomy bleeding and postendoscopic papillectomy bleeding, though specific numerical data for these outcomes were not detailed in the primary results summary. The study noted 1,865 cases of post-ERCP bleeding as a primary safety metric. No specific data regarding serious adverse events or discontinuation rates were reported.

These findings provide a comprehensive overview of the risk landscape for ERCP procedures. While the study identifies several significant risk factors, it is important to note that the data are based on a meta-analysis of observational and prospective studies, meaning these results represent associations rather than direct causal links. The large sample size of 149,870 provides a robust basis for identifying these specific risk factors in the clinical population.

Several factors were not reported or were not found to have a significant association in this specific analysis, including high body mass index (BMI), nonsteroidal anti-inflammatory drug (NSAID) use, antiplatelet therapy, thrombocytopenia, common bile duct stones, cholangitis, endoscopic papillary balloon dilatation, covered self-expandable metal stent insertion, age, choledocholithiasis, pancreatic duct stones, and needle-knife sphincterotomy. These exclusions help clarify that the primary drivers of risk are related to underlying coagulopathy and specific procedural complexities.

Clinically, these results are highly relevant for identifying patients who may require more intensive monitoring or specialized management during and after ERCP. Specifically, patients with coagulopathy, those on hemodialysis, and those with cirrhosis should be flagged as high-risk. These findings can directly inform the informed consent process, ensuring that patients with these specific comorbidities are aware of their increased risk of bleeding. Furthermore, the identification of procedural risks, such as endoscopic sphincterotomy and precut sphincterotomy, allows for more tailored clinical decision-making regarding technique selection.

Questions remain regarding the specific management protocols that most effectively mitigate these risks in high-risk populations. Additionally, the lack of data on specific secondary outcomes like postendoscopic papillectomy bleeding limits the ability to tailor interventions for those specific procedures. Future research may focus on the specific interventions that can mitigate the high odds of bleeding in patients with coagulopathy or those undergoing hemodialysis.